Recently, a Phase IB Trial of autologous CIK cells in combination with Sintilimab, (mAb PD-1), plus chemotherapy in patients with advanced NSCLC also showed encouraging efficacy (NCT03987867) [92]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.